Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

Tsuyoshi Takahashi MD, Makoto Sonobe MD, PhD, Masashi Kobayashi MD, Akihiko Yoshizawa MD, Toshi Menju MD, Ei Nakayama MD, Nobuya Mino MD, PhD, Shotaro Iwakiri MD, PhD, Kiyoshi Sato MD, PhD, Ryo Miyahara MD, PhD, Kenichi Okubo MD, PhD, Toshiaki Manabe MD, PhD, Hiroshi Date MD, PhD
Translational Research and Biomarkers
Volume 17, Issue 3 / March , 2009

View full article HTML | View full article PDF | Download Citation

Abstract

Background

A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) has recently been identified in non-small-cell lung cancers (NSCLCs). We screened for EML4–ALK fusion genes and examined the clinicopathological and genetic characteristics of fusion-harboring NSCLC tumors.

Methods

We examined 313 NSCLC samples from patients who underwent resection at our hospital between May 2001 and July 2005. We screened for the fusion genes using reverse-transcription polymerase chain reaction (RT-PCR) assay and confirmed the results with direct sequencing. We also examined mutations in the epidermal growth factor receptor (EGFR), KRAS, and ERBB2 genes.

Results

Five EML4–ALK fusion genes were detected (four from 111 female samples and one from 202 male samples; 1.6% overall). All five genes were found in adenocarcinomas and accounted for 2.4% of the 211 adenocarcinoma samples. One EML4–ALK fusion was variant 1, and two were variant 3. In addition, we also found two new fusion variants. Patients with fusion-positive tumors were nonsmokers or light smokers. Among the 211 adenocarcinomas, mutations in EGFR, KRAS, and ERBB2 were detected in 105, 29, and 7 tumors, respectively. Interestingly, all of the fusion-positive NSCLCs had no mutations within these genes.

Conclusions

EML4–ALK fusion genes were observed predominantly in adenocarcinomas, in female or nonsmoking populations. Additionally, the EML4–ALK fusions were mutually exclusive with mutations in the EGFR, KRAS, and ERBB2 genes.

Go to Issue Contents